...
首页> 外文期刊>Bioanalysis >Toxicokinetic evaluation of atrasentan in mice utilizing serial microsampling: Validation and sample analysis in GLP study
【24h】

Toxicokinetic evaluation of atrasentan in mice utilizing serial microsampling: Validation and sample analysis in GLP study

机译:利用系列微量进样对阿曲生坦的小鼠毒性动力学评估:GLP研究中的验证和样品分析

获取原文
获取原文并翻译 | 示例

摘要

A semi-automated 96-well protein precipitation followed by HPLC-MS/MS method for the determination of atrasentan (2R-[4-methoxyphenyl]-4S-[1,3- benzodioxol-5-yl]-1-[N,N-di-(N-butyl)-aminocarbonyl-methyl]-pyrrolidine-3R- carboxylic acid) in mouse whole blood was developed, validated and utilized in GLP toxicokinetic evaluations. Six 40-l whole blood samples were collected from a single mouse over the course of a 12 h blood collection window. To avoid sample volume losses, whole blood was selected as the matrix in place of the more typically used plasma. A 10-l assay volume was used to ensure sufficient volumes are available for dilutions, repeats and incurred sample reanalysis. The samples (10-l aliquot) were fortified with stable-labeled internal standard (d18-atrasentan) and lysed thoroughly prior to protein precipitation. The chromatographic separation was performed on a Zorbax ? SB-C18 (50 x 2.1 mm; 5 m) HPLC column with a mobile phase consisting of 25 mM ammonium acetate and 0.25% (v/v) acetic acid in 50/50 (v/v) acetonitrile/water. The MS measurement was conducted under positive ion mode using multiple-reaction monitoring of m/z 511→354 for analyte and 529→354 for stable-labeled internal standard. The peak area ratio (analyte:stable-labeled internal standard) was used to quantitate atrasentan. Results: A dynamic range of 5-1400 ng/ml was established after validation. The challenges associated with a small-volume whole-blood assay involved anticoagulant overloading with commercial blood collection tubes, managing phospholipids to ensure a robust assay and automation. In-depth discussions are provided in this article. The validated method was then used for GLP toxicokinetic evaluations. To demonstrate the method reproducibility, approximately 10% of the incurred samples from the study were repeated in singlet. Excellent assay reproducibility was demonstrated where 100% of samples met incurred sample reanalysis acceptance criteria. Conclusion: Good quality exposure data were obtained from every serial sampled mouse in the study.
机译:半自动沉淀96孔蛋白质,然后用​​HPLC-MS / MS方法测定阿曲生坦(2R- [4-甲氧基苯基] -4S- [1,3-苯并二恶唑-5-基] -1- [N,小鼠全血中的N-二-(N-丁基)-氨基羰基-甲基]-吡咯烷-3R-羧酸被开发,验证并用于GLP毒代动力学评估。在12小时的采血窗口中,从一只小鼠身上采集了六份40-l的全血样品。为避免样品量损失,选择全血作为基质来代替更常用的血浆。 10-l分析体积用于确保有足够的体积用于稀释,重复和引起样品重新分析。用稳定标记的内标(d18-阿特拉森坦)强化样品(10-1等份),并在蛋白沉淀之前彻底溶解。色谱分离在Zorbax TM上进行。 SB-C18(50 x 2.1 mm; 5 m)HPLC色谱柱,流动相由在50/50(v / v)乙腈/水中的25 mM乙酸铵和0.25%(v / v)乙酸组成。 MS测量是在正离子模式下进行的,使用多反应监测对分析物进行m / z 511→354,对稳定标记的内标进行529→354监测。峰面积比(分析物:稳定标记的内标)用于定量阿曲生坦。结果:验证后建立了5-1400 ng / ml的动态范围。小批量全血测定法面临的挑战包括商业采血管中的抗凝剂超负荷,管理磷脂以确保可靠的测定法和自动化。本文提供了深入的讨论。然后将经过验证的方法用于GLP毒性动力学评估。为了证明方法的可重复性,单重重复了大约10%的研究样品。在100%的样品满足样品再分析接受标准的情况下,证明了出色的测定重现性。结论:从研究中的每只串行采样小鼠获得了高质量的暴露数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号